Management of Patients Eligible for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals
Global and Regional Health Technology Assessment - Italy
doi 10.1177/2284240319861375
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2019
Authors
Publisher
Aboutscience Srl